Annual Report

Overview

The report records consolidated net sales of ¥1,452,759 million, up 19.3%, and operating income of ¥198,703 million, up 17.1%. It highlights Otsuka Pharmaceutical's acquisition of Astex in October 2013, adding oncology pipeline and drug-discovery capabilities. The report also describes Japan's 2014 approval of tolvaptan as an ADPKD treatment, the first approval of the drug for that condition worldwide.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2013-2014
Period: 1 April 2013 – 31 March 2014
Language: English
Pages
File size
Restatement: Disclosed

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services